Suppr超能文献

基于5-(色氨酰基)氨基-1,3-二氧代全氢吡啶并[1,2-c]嘧啶的强效和选择性CCK(1)受体拮抗剂:N2位取代基的构效关系研究

5-(Tryptophyl)amino-1,3-dioxoperhydropyrido[1,2-c]pyrimidine-based potent and selective CCK(1)receptor antagonists: structure-activity relationship studies on the substituent at N2-position.

作者信息

Bartolomé-Nebreda J M, Patiño-Molina R, Martín-Martínez M, Gómez-Monterrey I, García-López M T, González-Muñiz R, Cenarruzabeitia E, Latorre M, Del Río J, Herranz R

机构信息

Instituto de Química Médica (CSIC), Juan de la Cierva 3, E-28006 Madrid, Spain.

出版信息

J Med Chem. 2001 Jun 21;44(13):2219-28. doi: 10.1021/jm010813d.

Abstract

To establish structure-activity relationships a new series of analogues of the highly potent and selective CCK(1) receptor antagonist (4aS,5R)-2-benzyl-5-(N-Boc-tryptophyl)amino-1,3-dioxoperhydropyrido[1,2-c]-pyrimidine (1a) modified at N2-position of the central scaffold has been prepared and evaluated as CCK receptor ligands. With this aim the N2-benzyl group has been replaced by methyl, cyclohexyl, aromatic groups, 1-phenylethyl, and 1-carboxy-2-phenylethyl group. Then, substituents with different electronic and steric properties were introduced into different positions of the phenyl group of analogues 19a and 19b. The results of the CCK receptor binding and in vitro functional activity evaluation suggest the importance of the lipophilic character and an appropriate spatial orientation of the moiety linked at the N2-position of the 1,3-dioxoperhydropyrido[1,2-c]pyrimidine template for potent and selective binding and antagonist activity at CCK(1) receptor subtype. The 2-cyclohexyl and (2S)-1-naphthyl derivatives 18a and (2S)-20a have emerged as more potent and selective CCK(1) receptor antagonists than the lead compound 1a. Additionally, the results confirm the (4aS,5R)-stereochemistry at the central bicyclic skeleton as an essential structural requirement for potent binding to this receptor subtype.

摘要

为了建立构效关系,已制备了一系列新型类似物,它们是在中心骨架的N2位进行修饰的高效且选择性的CCK(1)受体拮抗剂(4aS,5R)-2-苄基-5-(N-Boc-色氨酰)氨基-1,3-二氧代氢化吡啶并[1,2-c]嘧啶(1a),并作为CCK受体配体进行了评估。为此,N2-苄基已被甲基、环己基、芳基、1-苯乙基和1-羧基-2-苯乙基取代。然后,将具有不同电子和空间性质的取代基引入类似物19a和19b苯基的不同位置。CCK受体结合和体外功能活性评估结果表明,对于在CCK(1)受体亚型上实现强效和选择性结合及拮抗剂活性,1,3-二氧代氢化吡啶并[1,2-c]嘧啶模板N2位连接部分的亲脂性特征和适当的空间取向很重要。2-环己基和(2S)-1-萘基衍生物18a和(2S)-20a已成为比先导化合物1a更有效和更具选择性的CCK(1)受体拮抗剂。此外,结果证实中心双环骨架上的(4aS,5R)立体化学是强效结合该受体亚型的必要结构要求。

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验